# Measure whether a video second check before chemotherapy at home is as safe as two nurses in the room

Source: https://onco.cc/ideas/idea-upgrade-video-second-check-safety-study/  
OnCo record `idea-upgrade-video-second-check-safety-study` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Before chemotherapy is given, two trained staff check the drug, the dose and the patient. When treatment is given at home, the second person may now join by video. The 2024 US standards allow this but say no well-designed study has measured whether it is as safe.

## Summary

The standard. The ASCO-ONS Antineoplastic Therapy Administration Safety Standards (2024) added a fourth verification at the patient's side and allow the second clinician to take part "through appropriate institutionally approved video-enabled technology, with at least one person on site".

The gap. The same document says that a review of remote verification found it "is feasible and may be alike live two-person checks; however, no well-designed research has evaluated the impact on safety", and cautions that reliance on technology can still lead to medication errors. Home administration is growing, so the number of checks done this way is likely to grow with it; how often it is used has not been measured.

## Fields

- Kind: Idea
- Last checked: 2026-11-11
- Tags: protocol-upgrade; upgrade:untested; evidence:insufficient
- Hypothesis: Video-enabled second verification at home detects the same proportion of planted and real discrepancies (wrong dose, wrong rate, wrong patient identifier, wrong administration set) as an in-person second check, without lengthening the visit.
- Rationale: The fourth verification exists because drugs are now prepared away from where they are given. If the remote version misses errors that an in-person check catches, the safeguard is weaker exactly where supervision is thinnest.
- Proposed test: A simulation study with seeded errors comparing in-person and video second checks, followed by a prospective audit across home infusion services of discrepancies caught, near misses and errors reaching the patient under each method.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Siegel et al., Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards (JCO Oncol Pract 2024): https://doi.org/10.1200/OP.24.00216

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- technologies: [Infusion pumps, ports, and ambulatory chemotherapy devices](https://onco.cc/technologies/infusion-devices-vascular-access/), [Smart infusion pumps with drug libraries (Novum IQ, Plum, Infusomat Space, Agilia, Ivenix)](https://onco.cc/technologies/smart-infusion-pumps/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/)
- protocols: [Anticancer treatment administration checks at the chair: assessment, independent double checks and line tracing](https://onco.cc/protocols/sact-administration-checks-at-the-chair/)

---
JSON: https://onco.cc/api/v1/entities/idea-upgrade-video-second-check-safety-study.json